SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

MaxCyte, Inc. (MXCT) News

Follow MaxCyte, Inc. (MXCT) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 18 public stories across 8 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol MXCT Asset equity Sector Markets 90 days 13 Last 1.375 Updated Nov 10, 2026, 02:04 PM UTC Open live news feed Open MXCT chart & news
M MaxCyte Reports Q3 Revenue of $10.2 Million, Raises 2026 Guidance MaxCyte reported $8.2 million in core revenue and $2.0 million in SPL Program-related revenue for the quarter ended September 30, 2026. It raised full-year 2026 total revenue guidance to at least $34.5 million. EQUITY | Nov 10, 2026, 02:04 PM UTC M MaxCyte Reports Third-Quarter 2026 Results, Updates Revenue Guidance MaxCyte reported third-quarter 2026 financial results and updated its full-year 2026 total revenue guidance. EQUITY | Nov 10, 2026, 11:07 AM UTC M MaxCyte to Buy Akron BioProducts for $151.8 Million MaxCyte agreed to buy Akron BioProducts from Arcline Investment Management for $151.8 million. MNA | Nov 10, 2026, 11:02 AM UTC M MaxCyte to Acquire Akron Bio, Expects to Nearly Double Revenue Base MaxCyte says the acquisition will expand its cell therapy manufacturing offerings and expects to nearly double its revenue base. EQUITY | Nov 10, 2026, 11:02 AM UTC M MaxCyte Reports Q3 Adjusted EBITDA of -$5.1 Million MaxCyte reported Q3 net income of -$4.8 million. Adjusted EBITDA was -$5.1 million versus an IBES estimate of -$7.99 million. EARNINGS | Nov 10, 2026, 11:02 AM UTC M MaxCyte Q3'26 Earnings Preview: EPS Estimated at (0.08) USD MaxCyte is scheduled to report Q3'26 results on November 10 after the market close. Revenue is estimated at USD 7.39 million, with EPS estimated at (0.08) USD. EQUITY | Nov 09, 2026, 12:01 PM UTC M MaxCyte raises 2026 revenue guidance after preliminary Q3 growth MaxCyte reported preliminary Q3 core revenue growth of 26% and raised its 2026 revenue guidance. Its shares are trading higher. EQUITY | Oct 14, 2026, 01:05 PM UTC M MaxCyte Reports Preliminary Q3 2026 Revenue and Raises FY 2026 Revenue Guidance EQUITY | Oct 14, 2026, 12:14 PM UTC L MaxCyte, Inc. (MXCT) Appoints Chief Corporate Development Officer MaxCyte appointed Sidharth Kapileshwar as Chief Corporate Development Officer. He previously held leadership roles at Danaher, GE Healthcare, Beckman Coulter, and Halma.Material DetailsContext by AI AnalystThis is an ear NEWS | Sep 23, 2026, 12:11 PM UTC L MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. NASDAQ:MXCT, a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of nex NEWS | Sep 23, 2026, 12:11 PM UTC L MXCT - MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer MXCT - MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer NEWS | Sep 23, 2026, 12:05 PM UTC L MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. NASDAQ:MXCT, a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercializatio NEWS | Sep 11, 2026, 08:32 PM UTC L MXCT - MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MXCT - MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEWS | Sep 11, 2026, 08:30 PM UTC L MaxCyte launches CHANGE-seq-BE and ONE-seq-BE assays MaxCyte (NASDAQ: MXCT) announces the launch of CHANGE-seq-BE and ONE-seq-BE off-target nomination assays through its SeQure service for adenine and cytosine base editors. REGULATION | Aug 19, 2026, 12:07 PM UTC L MaxCyte (MXCT) launches CHANGE-seq-BE and ONE-seq-BE off-target tools MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ aimed at strengthening off-target assessment for genome editing therapies. EQUITY | Aug 19, 2026, 12:05 PM UTC L MaxCyte Affirms FY2026 Sales Guidance MaxCyte affirms FY2026 sales outlook of $30.000M-$32.000M EARNINGS | Aug 12, 2026, 08:09 PM UTC L MXCT Reports Q2 2026 Financial Results MaxCyte reports second quarter 2026 financial results EARNINGS | Aug 12, 2026, 08:07 PM UTC L MXCT maxcyte® announces multi-platform technology license partnership with genentech® to advance cell therapy development Maxcyte - genentec MXCT maxcyte® announces multi-platform technology license partnership with genentech® to advance cell therapy development Maxcyte - genentech to access Maxcyte expert gtx platform and technologies for cell therapy workfl EQUITY | Jul 21, 2026, 12:46 PM UTC